Table 3.
Meta-analysis evaluating the adjusted association between HBV infection and NHL subtypes and by region
| Type | overall OR | High prevalence countries OR (95% CI) | Intermediate prevalence countries OR (95% CI) | Low prevalence countries OR (95% CI) |
|---|---|---|---|---|
| NHL |
2.09 (1.76–2.50) (*P < 0.01) n = 35 |
2.20 (1.78–2.72) (P < 0.01) n = 15 |
2.48 (1.55–3.95) (P < 0.01) n = 10 |
1.64 (1.15–2.34) (P < 0.01) n = 10 |
| DLBCL |
2.15 (1.52–3.02) (P < 0.01) n = 14 |
2.69 (1.88–3.86) (P < 0.01) n = 6 |
3.38 (2.13–5.36) (P = 0.47) n = 3 |
1.14 (0.58–2.26) (P < 0.01) n = 5 |
| BL | 2.22 (0.87–5.66) (P < 0.01) n = 7 |
1.50 (0.94–2.40) (P = 0.79) n = 6 |
n = 0 | n = 1 |
| CLL/SLL | 1.37 (0.93–2.00) (P < 0.01) n = 11 |
1.61 (1.00–2.58) (P = 0.09) n = 5 |
n = 1 |
1.33 (0.66–2.67) (P = 0.02) n = 5 |
| FL | 1.81 (1.12–2.94) (P < 0.01) n = 13 |
2.42 (1.36–4.32) (P < 0.01) n = 6 |
4.17 (2.06–8.46) (P = 0.71) n = 2 |
0.85 (0.44–1.66) (P = 0.02) n = 5 |
| NK/T |
1.30 (0.82–2.08) (P = 0.06) n = 7 |
1.23 (0.76–1.89) (P = 0.04) n = 5 |
4.51(0.56–36.25) (P = 0.57) n = 2 |
n = 0 |
| PTCL | 1.31 (0.89–1.91) (P = 0.44) n = 4 |
1.31 (0.89–1.91) (P = 0.44) n = 4 |
n = 0 | n = 0 |
| ALCL | 3.23 (1.27–8.18) (P = 0.04) n = 3 |
3.23 (1.27–8.18) (P = 0.04) n = 3 |
n = 0 | n = 0 |
Abbreviations: NHL = non-Hodgkin lymphoma, HBV = hepatitis B virus, OR = odds ratio, CI = confidence interval, DLBCL = diffuse large B-cell lymphoma, BL = Burkitt’s lymphoma, FL = follicular lymphoma, CLL/SLL = small lymphocytic lymphoma/chronic lymphocytic leukemia, NK/T = NK/T cell lymphoma, PTCL = peripheral T-cell lymphoma, ALCL = anaplastic large cell lymphoma. * Statistically significant at the 0.05 alpha level